A process for preparing and purifying alfaxalone (3α-hydroxy-5α-pregnane) from a crude mixture of 3α- and 3β-hydroxy-5α-pregnane; and subsequent purification of the 17α- and 17β-enantiomers to obtain the 17β- enantiomer (alfaxalone).
A method of improving the consistency and/or quality of a feline antibody is provided. The method includes expressing nucleotide sequence encoding a feline IgG kappa light chain and nucleotide sequence encoding a feline IgG heavy chain in a host cell to produce a feline antibody, wherein the nucleotide sequence encoding the feline IgG kappa light chain comprises a kappa light chain constant nucleotide sequence in which sequence encoding a C-terminal QRE sequence otherwise present in a wild-type feline IgG kappa light chain constant region is absent.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
This disclosure provides a method of protecting a canine against canine distemper virus, the method comprising administering a recombinant oral vaccine comprising a modified live canine adenovirus type 2 (CAV-2) vector carrying a Canine Distemper Virus (CDV) antigen to said canine, wherein the vaccine is administered orally.
The present invention describes the use of zoalene for admixture into livestock feed, preferably feed for swine and cattle, for increased weight gain and/or improved feed efficiency.
The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 29/02 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
Disclosed are salmon interferon sequences useful as adjuvants in fish vaccines. Also disclosed are fish vaccines utilizing said interferon sequences and methods for prevention of fish infections utilizing these vaccines.
The present invention describes a process for preparing a cold premix hexaflumuron solution in water, preferably sea water, with a salinity of about 3.5% to about 18%, preferably from about 3.5% to about 14%; and at a temperature of about 0ºC to about 12ºC, preferably at about 4°C, and wherein the cold premix solution is then further added to sea water with fish for the treatment of the fish against sea lice.
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 47/34 - Ureas or thioureas containing the groups N—CO—N or N—CS—N containing the groups , e.g. biuretThio-analogues thereofUrea-aldehyde condensation products
The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.
The invention provides a vaccine against C. chauvoei, the vaccine comprising a C. chauvoei component and additional cctA protein. The methods of making and using said vaccine are also provided.
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
ZOETIS SERVICES LLC (USA)
Inventor
Zhang, Jianqiang
Chen, Qi
Gauger, Phillip
Madson, Darin
Hardham, John Morgan
Bandrick, Meggan
Calvert, Jay Gregory
Thompson, James Richard
Stoeva, Mira Ivanova
Valdez, Walter
Abstract
The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus (“PEDV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.
Antimicrobial peptides of general formula X0X1X2C X3X4X5CX6X7X8X9CYX10X11CX12X13 are provided. Also provided are certain formulations containing these peptides and methods of using these peptides for treating skin infections in an animal in need thereof.
The invention provides an isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, wherein the antibody antagonizes IL-31-mediated signaling or OSM-mediated signaling or both in a canine and/or feline cell.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed is a system for targeting expression of antigens delivered via DNA vaccines to cell surface. Antigens, vaccines, and methods of using of these vaccines in prevention of fish from infections are also disclosed.
Disclosed are salmon interferon sequences useful as adjuvants in fish vaccines. Also disclosed are fish vaccines utilizing said interferon sequences and methods for prevention of fish infections utilizing these vaccines.
The present invention relates to nanostructure-binding partner conjugates, as well as reaction mixtures, analyte detection devices, and methods of making and using the conjugates. In particular, the invention provides a method of detecting a target analyte in a sample comprising mixing the sample with a first detection conjugate and a second detection conjugate in solution, wherein the first and second detection conjugates comprise metallic nanostructures coupled to binding partners that are capable of specifically binding to the target analyte if present in the sample to form a complex between the first detection conjugate, the analyte, and the second detection conjugate, wherein a change in an optical signal upon complex formation indicates the presence of the target analyte in the sample.
The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving its half-life and other characters.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Medical diagnostic systems for humans, comprising bodily
fluid analyzer, molded plastic containers for processing and
analyzing fluids and holding diagnostic reagents and
chemical reagents; electrical testing apparatus for medical
purposes, namely blood testing apparatus containing reagents
for clinical, medical and laboratory use.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer software programs for use in connection with a system for analyzing blood. Veterinary diagnostic system sold as a unit comprising blood analyzing apparatus for disposable cartridges and chemical reagents for use therein; cartridge, sold empty, for use in portable clinical blood analyzers for veterinary use. Providing temporary use of non-downloadable computer software programs for use in analyzing blood.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Computer software programs for use in connection with a system for analyzing blood
(2) Veterinary diagnostic system sold as a unit comprising blood analyzing apparatus for disposable cartridges and chemical reagents for use therein; cartridge, sold empty, for use in portable clinical blood analyzers for veterinary use (1) Providing temporary use of non-downloadable computer software programs for use in analyzing blood
The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving various characteristics.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed is a mutated E2 protein of Salmonid alphavirus. An attenuated Salmonid Alphavirus comprising this protein as well as the methods of using and methods of detecting said attenuated virus are also disclosed.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical diagnostic systems for animals, comprising bodily fluid analyzer, molded plastic containers for processing and analyzing fluids and holding diagnostic reagents and chemical reagents; electrical instruments, namely blood testing apparatus containing reagents for clinical, medical and laboratory use.
Provided herein are methods for measuring concentration of circulating cell free DNA (cfDNA) from a sample of a subject, for the purposes of cancer or tumor detection and/or characterization.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
39.
RECOMBINANT HERPESVIRUS OF TURKEY VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF
The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.
Provided herein are methods for measuring concentration of circulating cell free DNA (cfDNA) from a sample of a subject, for the purposes of cancer or tumor detection and/or characterization.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
Medical diagnostic systems for animals, comprising bodily fluid analyzer, molded plastic containers for processing and analyzing fluids and holding diagnostic reagents and chemical reagents; electrical instruments, namely blood testing apparatus containing reagents for clinical, medical and laboratory use
The invention provides compositions and methods for treating mastitis. Specifically, the invention provides cathelicidin peptides for treating mastitis.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 15/14 - Drugs for genital or sexual disordersContraceptives for lactation disorders, e.g. galactorrhoea
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention describes a process for degrading an isoxazoline from waste sea water treated with an isoxazoline that was used to treat fish against sea lice infestation by optionally adjusting the pH of the water to a pH range of about 9-10 with a base; ozonating the water to achieve a total residual oxidant (TRO) level of about 2 to 9 mg/L; preferably, 3 to 8 mg/L; after ozonation, incubating the water for a period of 0 to about 24 hours; neutralizing the waste sea water after the incubation period by adding a reducing agent; and finally discharging the treated waste sea water back into the environment.
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
50.
TOPICAL COMPOSITIONS CONTAINING A JANUS KINASE INHIBITOR
The present invention describes a topical veterinary solution composition comprising a JAK inhibitor, preferably oclacitinib, or a pharmaceutically acceptable salt thereof, for use on animals, preferably canine, for the treatment of dermatological disorders, for example, allergic dermatitis, atopic dermatitis, pruritis and/or a hot spot(s).
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
The disclosure provides a C-terminally truncated Spike protein of PEDV. Nucleic acid sequences including same and a virus comprising same, as well as methods of use are also provided.
The present invention provides a method of preparing a milk sample for a downstream nucleic acid amplification process. This method includes: subjecting a milk sample comprising at least one suspected bacterial pathogen implicated in mastitis to contact with uncoated magnetic beads; incubating the milk sample in the presence of the uncoated magnetic beads to allow bacterial cells in the milk sample to bind to the beads, thereby forming a bead-bacterium complex; subjecting the bead-bacterium complex to a magnet such that the bead-bacterium complex is separated from a milk sample supernatant; removing the milk sample supernatant; directly resuspending the separated bead-bacterium complex in an aqueous solution to release the bead-bound bacteria into the solution; and employing an aliquot of the bead resuspension or bead-free supernatant following separation of the beads as a template for primer-specific downstream nucleic acid amplification.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.
This disclosure provides an attenuated suid herpesvirus 1 (a Pseudorabies virus) wherein the TK, gl and gE genes thereof are modified relative to a parent field strain, such that the resultant virus is safe and effective for use as a live vaccine that protects swine animals from challenge with a virulent Pseudorabies virus.
A gas-actuated needle-free injector is provided. Such gas-actuated needle-free injector includes a gas spring in communication with a piston. A vaccine dosing chamber is configured to receive one or more vaccines or components thereof. A ball screw is coaxial with the gas spring and the vaccine dosing chamber and configured to receive at least portion of the piston. The ball screw is configured to move the piston between a first position and a second position. Associated systems and methods are also provided.
A gas-actuated needle-free injector is provided. Such gas-actuated needle-free injector includes a gas spring in communication with a piston. A vaccine dosing chamber is configured to receive one or more vaccines or components thereof. A ball screw is coaxial with the gas spring and the vaccine dosing chamber and configured to receive at least portion of the piston. The ball screw is configured to move the piston between a first position and a second position. Associated systems and methods are also provided.
United States of America, as represented by the Secretary of Agriculture (USA)
Inventor
Dominowski, Paul Joseph
Hardham, John Morgan
Jackson, James Alan
Gay, Cyril Gerard
Rodriguez, Luis Leandro
Krug, Peter William
Rieder, Aida Elizabeth
Abstract
Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.
This disclosure provides an attenuated suid herpesvirus 1 (a Pseudorabies virus) wherein the TK, gI and gE genes thereof are modified relative to a parent field strain, such that the resultant virus is safe and effective for use as a live vaccine that protects swine animals from challenge with a virulent Pseudorabies virus.
This disclosure provides a vaccine comprising a modified live PRRS-1 virus attenuated in cells expressing porcine CD163 for use in inducing protective immunity in a piglet that is older than 60 hours of age, wherein said vaccine is administered to said piglet intranasally.
The instant disclosure provides a bait vaccine formulation for swine, the formulation comprising an antigen; optionally, an adjuvant, and a matrix, wherein said antigen is inside of a container, wherein said container is entirely within the matrix, wherein the matrix is not coated by a protective film, wherein said bait formulation is temperature stable and/or humidity stable and/or suitable for aerial deployment. Methods of using these bait vaccine formulations are also provided.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing access to a digital tool in the nature of online non-downloadable software that serves as a portal to allow cat owners to upload videos of their cats in order to access an artificial intelligence program which evaluates cat videos for signs of cat osteoarthritis pain and provides an assessment to a veterinarian who will make recommendations for treatment options Providing information online in the field of feline osteoarthritis
An apparatus for singulating organisms includes a chute, an output nozzle, and a valve. The chute includes a first chute end that is open to receive a plurality of organisms and a second chute end. The output nozzle is formed in a funnel shape and has a first nozzle end and a second nozzle end. The valve is attached to the second chute end and the first nozzle end. The valve is movable to a range of positions including an open position and a closed position. One organism travels to and blocks the second nozzle end and another organism travels to the second chute end. The organism that is positioned at the output nozzle is discharged from the singulating device upon movement of the valve from the open position to the closed position.
An apparatus for singulating organisms includes a chute, an output nozzle, and a valve. The chute includes a first chute end that is open to receive a plurality of organisms and a second chute end. The output nozzle is formed in a funnel shape and has a first nozzle end and a second nozzle end. The valve is attached to the second chute end and the first nozzle end. The valve is movable to a range of positions including an open position and a closed position. One organism travels to and blocks the second nozzle end and another organism travels to the second chute end. The organism that is positioned at the output nozzle is discharged from the singulating device upon movement of the valve from the open position to the closed position.
Provided herein are methods and kits for measuring fragment size distribution of DNA fragments from a sample of a subject, for the purposes of cancer or tumor detection, characterization, and/or management.
Medical diagnostic apparatus for testing animals, incorporating a bodily fluid analyzer incorporating and molded plastic containers for processing and analyzing fluids and holding diagnostic reagents and chemical reagents; electrical instruments, namely, blood testing apparatus containing reagents for clinical, medical and laboratory use.
72.
POULTRY VACCINES AND METHODS OF PROTECTING POULTRY
A method of protecting an offspring of a hen against infectious bronchitis infection is provided, the method comprising administering to said hen a vaccine comprising an inactivated infectious bronchitis virus and adjuvanted with water-in-oil emulsion and an immunostimulatory oligonucleotide.
Porcine IgG monoclonal antibodies (mAbs) can be effective therapeutics in veterinary medicine. Several years ago, six porcine IgG subclasses were identified. However, only a limited work has been done to improve the characteristics of porcine IgGs. The invention relates generally to porcine antibody mutants and uses thereof. Specifically, the invention relates to mutations in the constant region of porcine antibody for improving various characteristics.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Software comparing the genomic sequence of swine virus isolates (1) Veterinary laboratory services; Software as a Service for professionals in the veterinary sector
(2) Genetic testing of animals for diagnostic or treatment purposes
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Software comparing the genomic sequence of swine virus isolates (1) Veterinary laboratory services; Software as a Service for professionals in the veterinary sector
(2) Genetic testing of animals for diagnostic or treatment purposes
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
09 - Scientific and electric apparatus and instruments
Goods & Services
Sorting apparatus for selectively sorting clear eggs from viable eggs comprised of a mechanical selector for collecting a sample from the egg and analyzing the sample to determine the viability of the egg, and a mechanical egg sorter for sorting clear eggs
The invention relates generally to porcine antibody mutants and uses thereof. Specifically, the invention relates to mutations in the constant region of porcine antibody for improving various characteristics.
The invention relates generally to equine antibody mutants and uses thereof. Specifically, the invention relates to mutations in the constant region of equine antibody for improving various characteristics.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
The present invention provides a lateral flow device for detecting lipoteichoic acid (LT A) as a Gram-positive bacteria identifier in a milk sample of an animal. The device comprises: a) a strip formed of a material enabling capillary flow of fluid along a portion of the strip; b) a sample pad located proximal to one end of the strip for receiving the milk sample, c) a conjugate pad located in the strip so that in operation the sample flows under capillary action through the strip from the sample pad to the conjugate pad and mobilizes a conjugate contained in the conjugate pad, the conjugate comprising an anti-LTA antibody that has been conjugated to a detection agent, d) a test line Test Die comprising an anti-LTA antibody immobilized within the strip along a band located substantially perpendicular to the direction of the sample flow along the strip so that when a formed complex comprised of the mobilized anti-LTA antibody conjugate and the LT A in the sample contacts the immobilized anti-LTA antibody in the test line the presence of LT A in the sample is indicated by a visible color change.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
A microfluidic rotor for characterizing analytes in a fluid includes a plurality of cuvettes containing one or more selected reagent. The rotor further includes a plurality of cuvette marks. The rotor has a cuvette mark to cuvette ratio other than 1:1. For example, the ratio of the cuvette mark to the cuvette-receiving chamber may be, in certain instances, 1:4.
The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving its half-life and other characters.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A microfluidic rotor for characterizing analytes in a fluid includes a plurality of cuvettes containing one or more selected reagent. The rotor further includes a plurality of cuvette marks. The rotor has a cuvette mark to cuvette ratio other than 1:1. For example, the ratio of the cuvette mark to the cuvette-receiving chamber may be, in certain instances, 1:4.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
The invention relates generally to canine antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of canine antibody for improving various characteristics.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The invention relates generally to bovine antibody mutants and uses thereof. Specifically, the invention relates to mutations in the constant region of bovine antibody for improving various characteristics.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The United States of America, as represented by the Secretary of Agriculture (USA)
Zoetis Services LLC (USA)
Inventor
Jenkins, Mark C.
Schaeffer, Jonathan L.
Abstract
The drinking water-based avian coccidiosis vaccine formulation and delivery system is structured to deliver a vaccine containing live Eimeria oocysts to poultry house brood chamber chicks. The vaccine is delivered to the chicks in a diluted form through the poultry house drinking water system. The chicks are inoculated with the drinking water-based avian coccidiosis vaccine when they consume the water containing the vaccine. The timing of the chicks' drinking water access to the diluted drinking water vaccine is critical. During the inoculation process, water is temporarily withheld from the chicks for a waiting period of about 3-5 hours, and access to the diluted drinking water-based vaccine is limited to an accessibility period of about 2 hours. Additionally, metering valves and/or terminal metering valve assemblies are manually or automatically closed when the when the drinking water lines are fully charged with the diluted vaccine.
The disclosure relates generally to canine antibody variants and uses thereof. Specifically, the disclosure relates to mutations in the constant region of canine antibody for improving its half-life and other characters.
The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.
L'invention concerne d'une manière générale des variants d'anticorps canin et leurs utilisations. Plus précisément, l'invention concerne des mutations dans la région constante d'anticorps canins destinées à améliorer diverses caractéristiques.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The invention describes a long-acting composition comprising a spiro-azetidine isoxazoline of Formula (1) or (2)
The invention describes a long-acting composition comprising a spiro-azetidine isoxazoline of Formula (1) or (2)
The invention describes a long-acting composition comprising a spiro-azetidine isoxazoline of Formula (1) or (2)
wherein R1a, R1b, R1c and R2 are as described herein, and stereoisomers thereof. The composition is a veterinary composition and also comprises a glycol ether and at least one veterinarily acceptable solvent, and optionally, at least one precipitation inhibitor, antioxidant and additional veterinary agent, and any mixture thereof. The invention also includes a method of treating an animal with a parasitic infestation by administering the long-acting composition to the animal in need thereof.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 9/00 - Medicinal preparations characterised by special physical form
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
The invention relates generally to bovine antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of bovine antibody for improving various characteristics.
The invention relates generally to canine antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of canine antibody for improving various characteristics. The canine antibody variants comprise a modified IgG comprising: a canine IgG constant domain comprising at least one amino acid substitution relative to a wild-type canine IgG constant domain, wherein said substitution is at amino acid residue 286, 311, 312, 426, or 436, numbered according to the Eu index as in Kabat.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The invention relates generally to canine antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of canine antibody for improving various characteristics. The canine antibody variants comprise a modified IgG comprising: a canine IgG constant domain comprising at least one amino acid substitution relative to a wild-type canine IgG constant domain, wherein said substitution is at amino acid residue 286, 311, 312, 426, or 436, numbered according to the Eu index as in Kabat.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
